{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:42:21Z","timestamp":1784734941533,"version":"3.55.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004607","name":"Natural Science Foundation of Guangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004607","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82360526"],"award-info":[{"award-number":["82360526"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["americanjournalofsurgery.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Surgery"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.amjsurg.2025.116712","type":"journal-article","created":{"date-parts":[[2025,11,16]],"date-time":"2025-11-16T20:21:54Z","timestamp":1763324514000},"page":"116712","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Application of hepatic artery interventional therapies in the conversion treatment of unresectable hepatocellular carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"252","author":[{"given":"Yongchao","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shixun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-2273","authenticated-orcid":false,"given":"Yihe","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.amjsurg.2025.116712_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"10.1016\/j.amjsurg.2025.116712_bib2","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.1245\/s10434-019-07580-9","article-title":"Prognosis after resection of Barcelona Clinic Liver Cancer (BCLC) stage 0, A, and B hepatocellular carcinoma: a comprehensive assessment of the current BCLC classification","volume":"26","author":"Tsilimigras","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.amjsurg.2025.116712_bib3","first-page":"337","article-title":"Evidence-based medicine: treatment of chronic hepatitis C. Liege study group on viral hepatitis","volume":"55","author":"Delwaide","year":"2000","journal-title":"Rev Med Liege"},{"issue":"9","key":"10.1016\/j.amjsurg.2025.116712_bib4","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib5","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3390\/cancers11060873","article-title":"Multidisciplinary management of patients with unresectable hepatocellular carcinoma: a critical appraisal of current evidence","volume":"11","author":"Gholam","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.amjsurg.2025.116712_bib6","doi-asserted-by":"crossref","first-page":"3301","DOI":"10.1245\/s10434-007-9549-7","article-title":"Salvage surgery following downstaging of unresectable hepatocellular carcinoma - a strategy to increase resectability","volume":"14","author":"Lau","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib7","doi-asserted-by":"crossref","first-page":"807","DOI":"10.2147\/JHC.S408819","article-title":"Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with Lenvatinib and Anti-PD-1 antibodies for unresectable hepatocellular carcinoma: a retrospective analysis","volume":"10","author":"Wu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"issue":"3","key":"10.1016\/j.amjsurg.2025.116712_bib8","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s11845-022-03131-6","article-title":"Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients","volume":"192","author":"Zhu","year":"2023","journal-title":"Ir J Med Sci"},{"issue":"2","key":"10.1016\/j.amjsurg.2025.116712_bib9","doi-asserted-by":"crossref","DOI":"10.1097\/AS9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann Surg"},{"issue":"9","key":"10.1016\/j.amjsurg.2025.116712_bib10","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s12032-023-02082-x","article-title":"Analysis of the safety and effectiveness of TACE combined with targeted immunotherapy in the treatment of intermediate and advanced hepatocellular carcinoma","volume":"40","author":"Liu","year":"2023","journal-title":"Med Oncol"},{"issue":"5","key":"10.1016\/j.amjsurg.2025.116712_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/bjsopen\/zrac114","article-title":"Conversion therapy for initially unresectable hepatocellular carcinoma using a combination of toripalimab, lenvatinib plus TACE: Real-world study","volume":"6","author":"Qu","year":"2022","journal-title":"BJS Open"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s12072-024-10762-7","article-title":"HAIC plus lenvatinib and tislelizumab for advanced hepatocellular carcinoma with Vp4 portal vein invasion","volume":"19","author":"Tang","year":"2025","journal-title":"Hepatol Int"},{"key":"10.1016\/j.amjsurg.2025.116712_bib13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/CMAR.S481242","article-title":"The combination of d-tace-haic, lenvatinib, and pd-1 inhibitors shows significant clinical efficacy in patients with unresectable hepatocellular carcinoma","volume":"17","author":"Wu","year":"2025","journal-title":"Cancer Manag Res"},{"issue":"11","key":"10.1016\/j.amjsurg.2025.116712_bib14","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.2174\/1570180820666230601113529","article-title":"Analysis of the safety and effectiveness of Lenvatinib plus TACE-HAIC + PD-1 inhibitor for intermediate and advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2024","journal-title":"Lett Drug Des Discovery"},{"key":"10.1016\/j.amjsurg.2025.116712_bib15","first-page":"1","author":"Yang","year":"2025","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1186\/s12885-024-12484-3","article-title":"TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study","volume":"24","author":"Tang","year":"2024","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.amjsurg.2025.116712_bib17","doi-asserted-by":"crossref","first-page":"7860","DOI":"10.1245\/s10434-024-15933-2","volume":"31","author":"Chen","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2147\/JHC.S431917","article-title":"Tyrosine kinase inhibitors plus Anti-PD-1 antibodies with hepatic arterial infusion chemotherapy or transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"10","author":"Yu","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1186\/s12957-022-02717-9","article-title":"Callispheres drug-eluting beads transarterial chemoembolization might be an efficient and safety down-staging therapy in unresectable liver cancer patients","volume":"20","author":"Peng","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"8","key":"10.1016\/j.amjsurg.2025.116712_bib20","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1007\/s00432-021-03767-4","article-title":"Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study","volume":"148","author":"Chen","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib21","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.2147\/DDDT.S266470","article-title":"Efficacy and safety of supplemental transarterial chemoembolization through extrahepatic collateral arteries with drug-eluting beads: treatment for unresectable hepatocellular carcinoma","volume":"14","author":"Chiu","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.amjsurg.2025.116712_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40880-017-0251-2","article-title":"Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized","volume":"36","author":"He","year":"2017","journal-title":"Chin J Cancer"},{"key":"10.1016\/j.amjsurg.2025.116712_bib23","article-title":"Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis","volume":"15","author":"Yang","year":"2024","journal-title":"Front Pharmacol"},{"issue":"7","key":"10.1016\/j.amjsurg.2025.116712_bib24","doi-asserted-by":"crossref","first-page":"564","DOI":"10.2174\/1568009623666230215142941","article-title":"Transarterial chemoembolization followed by hepatic arterial infusion chemotherapy combined a tyrosine kinase inhibitor for treatment of large hepatocellular carcinoma","volume":"23","author":"Chen","year":"2023","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib25","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1111\/liv.12750","article-title":"Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma","volume":"35","author":"Kolligs","year":"2015","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib26","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1097\/JS9.0000000000001940","article-title":"Hepatic arterial chemotherapy infusion combined with tyrosine kinase inhibitors and PD-1 inhibitors for advanced hepatocellular carcinoma with high risk: a propensity score matching study","volume":"111","author":"Zuo","year":"2025","journal-title":"Int J Surg"},{"key":"10.1016\/j.amjsurg.2025.116712_bib27","first-page":"1","article-title":"Prognostic evaluation of conversion therapy following hepatic arterial infusion chemotherapy or immunotherapy in patients with advanced or transarterial chemoembolization unsuitable intermediate-stage hepatocellular carcinoma: a retrospective cohort study","author":"Kuo","year":"2024","journal-title":"Oncology"},{"issue":"8","key":"10.1016\/j.amjsurg.2025.116712_bib28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/1751-2980.13030","article-title":"Radioembolization vs sorafenib in locally advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score and Bayesian analysis","volume":"22","author":"Martelletti","year":"2021","journal-title":"J Dig Dis"},{"issue":"5","key":"10.1016\/j.amjsurg.2025.116712_bib29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1200\/JCO.21.01963","article-title":"Arterial chemotherapy of oxaliplatin plus fluorouracil versus Sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1)","volume":"40","author":"Lyu","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1200\/JCO.22.00392","article-title":"Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH)","volume":"41","author":"Peng","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211002720","article-title":"Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma","volume":"13","author":"He","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112711","article-title":"Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: a multi-center cohort study","volume":"139","author":"Huang","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib33","first-page":"755","article-title":"Clinical efficacy of targeted therapy, immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX), and lipiodol embolization in the treatment of unresectable hepatocarcinoma","volume":"73","author":"Lin","year":"2022","journal-title":"J Physiol Pharmacol"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21037\/jgo.2019.06.01","article-title":"Downstaging unresectable hepatocellular carcinoma by radioembolization using 90-yttrium resin microspheres: a single center experience","volume":"11","author":"Tabone","year":"2020","journal-title":"J Gastrointest Oncol"},{"issue":"17","key":"10.1016\/j.amjsurg.2025.116712_bib35","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.3748\/wjg.v30.i17.2321","article-title":"Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma","volume":"30","author":"Lin","year":"2024","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41392-024-01991-1","article-title":"Envafolimab plus lenvatinib and transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a prospective, single-arm, phase II study","volume":"9","author":"Chen","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.amjsurg.2025.116712_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1471017","article-title":"FOLFOX-HAIC combined with targeted immunotherapy for initially unresectable hepatocellular carcinoma: a real-world study","volume":"15","author":"Lu","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib38","article-title":"Hepatic arterial infusion chemotherapy combined with anti-PD-1\/PD-L1 immunotherapy and molecularly targeted agents for advanced hepatocellular carcinoma: a real world study","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1004652","article-title":"Hepatic arterial infusion chemotherapy combined with PD-1 inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a tertiary medical center experience","volume":"12","author":"Luo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib40","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.2147\/JHC.S332420","article-title":"Lenvatinib combined with Anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study","volume":"8","author":"Wu","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.amjsurg.2025.116712_bib41","article-title":"Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors","volume":"13","author":"Li","year":"2023","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.amjsurg.2025.116712_bib42","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.3748\/wjg.v21.i13.3970","article-title":"Oxaliplatin and 5-fluorouracil hepatic infusion with lipiodolized chemoembolization in large hepatocellular carcinoma","volume":"21","author":"Li","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.amjsurg.2025.116712_bib43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1007\/s00270-017-1874-z","article-title":"Phase II study of sorafenib combined with concurrent hepatic arterial infusion of Oxaliplatin, 5-Fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis","volume":"41","author":"He","year":"2018","journal-title":"Cardiovasc Interv Radiol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.112492","article-title":"Real-world efficacy and safety of TACE-HAIC combined with TKIs and PD-1 inhibitors in initially unresectable hepatocellular carcinoma","volume":"137","author":"Pang","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.amjsurg.2025.116712_bib45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2147\/JHC.S404500","article-title":"Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitor and immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a single center experience","volume":"10","author":"Pan","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"issue":"16","key":"10.1016\/j.amjsurg.2025.116712_bib46","first-page":"4079","article-title":"Safety and efficacy of transarterial chemoembolization combined with tyrosine kinase inhibitors and camrelizumab in the treatment of patients with advanced unresectable hepatocellular carcinoma","volume":"41","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib47","doi-asserted-by":"crossref","first-page":"811","DOI":"10.4149\/neo_2023_230806N413","article-title":"Sintilimab, bevacizumab biosimilar, and HAIC for unresectable hepatocellular carcinoma conversion therapy: a prospective, single-arm phase II trial","volume":"70","author":"Liu","year":"2023","journal-title":"Neoplasma"},{"key":"10.1016\/j.amjsurg.2025.116712_bib48","article-title":"Surgical conversion for initially unresectable locally advanced hepatocellular carcinoma using a triple combination of angiogenesis inhibitors, Anti-PD-1 antibodies, and hepatic arterial infusion chemotherapy: a retrospective study","volume":"11","author":"Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.amjsurg.2025.116712_bib49","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.21037\/tcr-24-93","article-title":"Transarterial chemoembolization (TACE)-hepatic arterial infusion chemotherapy (HAIC) combined with PD-1 inhibitors plus lenvatinib as a preoperative conversion therapy for nonmetastatic advanced hepatocellular carcinoma: a single center experience","volume":"13","author":"Zhao","year":"2024","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.amjsurg.2025.116712_bib50","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.2147\/JHC.S428980","article-title":"Transarterial chemoembolization plus lenvatinib and PD-1 inhibitors for hepatocellular carcinoma with main trunk portal vein tumor thrombus: a multicenter retrospective study","volume":"10","author":"Li","year":"2023","journal-title":"J Hepatocell Carcinoma"},{"key":"10.1016\/j.amjsurg.2025.116712_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102367","article-title":"Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study","volume":"67","author":"Wu","year":"2024","journal-title":"eClinicalMedicine"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib52","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3892\/ol.2024.14398","article-title":"Lenvatinib-based treatment regimens in conversion therapy of unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"27","author":"Li","year":"2024","journal-title":"Oncol Lett"},{"issue":"4","key":"10.1016\/j.amjsurg.2025.116712_bib53","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1572-0241.2007.01712.x","article-title":"Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness","volume":"103","author":"Sergio","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.amjsurg.2025.116712_bib54","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1177\/000313480206800920","article-title":"Transcatheter arterial chemoembolization with or without radiofrequency ablation in the management of patients with advanced hepatic malignancy","volume":"68","author":"Bloomston","year":"2002","journal-title":"Am Surg"},{"issue":"7","key":"10.1016\/j.amjsurg.2025.116712_bib55","first-page":"769","article-title":"Chinese expert consensus on neoadjuvant and conversion therapy for hepatocellular carcinoma (2023 edition)","volume":"22","author":"Cancer","year":"2023","journal-title":"Electron J Liver Cancer"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib56","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1186\/s12885-024-12772-y","article-title":"Systemic conversion therapies for initially unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"24","author":"Xu","year":"2024","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.amjsurg.2025.116712_bib57","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/cam4.5125","article-title":"TACE versus TARE for patients with hepatocellular carcinoma: overall and individual patient level meta analysis","volume":"12","author":"Brown","year":"2023","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib58","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jvir.2017.02.018","article-title":"Segmental Yttrium-90 radioembolization versus segmental chemoembolization for localized hepatocellular carcinoma: results of a single-center, retrospective, propensity score-matched study","volume":"28","author":"Padia","year":"2017","journal-title":"J Vasc Intervent Radiol"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib59","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 radioembolization significantly prolongs time to progression compared with chemoembolization in patients with hepatocellular carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"issue":"51","key":"10.1016\/j.amjsurg.2025.116712_bib60","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032390","article-title":"HAIC versus TACE for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine (Baltim)"},{"issue":"12","key":"10.1016\/j.amjsurg.2025.116712_bib61","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/1097-0142(20010615)91:12<2386::AID-CNCR1272>3.0.CO;2-4","article-title":"Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: a prospective study","volume":"91","author":"Song","year":"2001","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.amjsurg.2025.116712_bib62","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/jgh3.12573","article-title":"Transcatheter arterial infusion chemotherapy with cisplatin in combination with transcatheter arterial chemoembolization decreases intrahepatic distant recurrence of unresectable hepatocellular carcinoma","volume":"5","author":"Kawabe","year":"2021","journal-title":"JGH Open"},{"issue":"1","key":"10.1016\/j.amjsurg.2025.116712_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188391","article-title":"Lenvatinib for hepatocellular carcinoma: from preclinical mechanisms to anti-cancer therapy","volume":"1874","author":"Zhao","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"10","key":"10.1016\/j.amjsurg.2025.116712_bib64","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13411","article-title":"Clinical practice guidelines for hepatocellular carcinoma: the Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update","volume":"49","author":"Kokudo","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.amjsurg.2025.116712_bib65","article-title":"Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAR","author":"\u00d6cal","year":"2025","journal-title":"Eur Radiol"}],"container-title":["The American Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961025005355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002961025005355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:26:22Z","timestamp":1779297982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002961025005355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"alternative-id":["S0002961025005355"],"URL":"https:\/\/doi.org\/10.1016\/j.amjsurg.2025.116712","relation":{},"ISSN":["0002-9610"],"issn-type":[{"value":"0002-9610","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Application of hepatic artery interventional therapies in the conversion treatment of unresectable hepatocellular carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjsurg.2025.116712","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"116712"}}